PressRelease

ResearchArticle cites AlbuVoid™ in Stem Cell Secretome Characterization

MONMOUTHJUNCTION, NJ, January 19, 2026 — Biotech Support Group (BSG)reports on its NRicher™-derived product, AlbuVoid™, forsecretome analysis of a human induced pluripotent stem cell (hiPSC)-derived product to promote successful reproductive outcomes.

Researchinvestigators at Gameto Inc, published an article entitled“Developmentof human induced pluripotent stem cell-derived ovarian support cellsas a clinical-grade product for in vitro fertilization”,describing the analytical assessment required for the generation of aclinically suitable hiPSC-derived ovarian support cell (OSC) product.

TranscriptionFactor-mediated hiPSC differentiation generates OSCs that improve thein vitro maturation (IVM) of human oocytes. Quality, safety, andpotency of raw material upgrades were assessed to establish theclinical readiness of the product Fertilo. For this purpose, aproteomic comparison of conditioned media of Research Use Only(RUO)-OSCs versus clinical grade (CG)-OSCs was performed. The articlestates “The conditioned media were subjected to consecutivecentrifugations…to remove cellular remnants, and then passedthrough albumin depletion columns (AVK-50, AlbuVoid Albumin DepletionColumns Biotech Support Group) to eliminate HSA-derived albumin.”,prior to LCMS/MS analysis. The secretome analysis of both the RUO andCG lines revealed proteins associated with oocyte maturation anddevelopment competence, such as TGFB1, EGFR, and IGF2BP1/2/3, helpingto confirm clinical grade process optimization.

Thearticle concludes that the application of Fertilo in alongitudinal cohort analysis shows improvement in key outcomes,compared with traditional IVM. The findings demonstrate thefirst-time clinical development and application of an hiPSC-derivedproduct to promote successful reproductive outcomes.

“Proteomicstudies of cell secretomes have greatly increased in recent years. Amajor challenge however is analyzing the low abundance of the genuinesecreted proteins, over the highly abundant proteins derived from theserum containing media, the preponderance of which is serum albumin.As demonstrated here, AlbuVoid™ is perfected suited to enrich theAlbumin-depleted sub-proteome of cell secretomes.” stated Dr.Swapan Roy, President and Founder of Biotech Support Group.

Formore information visit: AlbuVoid™at
https://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

And AlbuVoid™ LC-MS On-BeadFor Serum/Plasma Proteomics, at

https://www.biotechsupportgroup.com/AlbuVoid-LC-MS-On-Bead-For-Serum-Proteomics-p/avb-ms.htm

For more information on our completeline of Albumin & IgG Removal, visit:

https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm

For more information on NRicher™for family=specific and targeted proteomics, visit:

https://www.biotechsupportgroup.com/category-s/340.htm

AboutBiotech Support Group LLC
BiotechSupport Group develops innovative sample preparation technologiesthat address the emerging needs of proteomics, biomarker discovery,and personalized medicine. Flagship products include Cleanascite™for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum proteindepletion, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NRicher™ for low abundance, family specific, and targetedproteome enrichment.These products support translational research by simplifyingworkflows and improving sample quality for downstream analysis.

ForBusiness Development Inquiries:
Matthew Kuruc
Phone:732-274-2866
Email: [email protected]

Keywords:AlbuVoid™, Albumin depletion, human induced pluripotent stem cells(hiPSCs), cell secretome